Literature DB >> 2577312

The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade.

M G Dodd1, D G Gardiner, A J Carter, M R Sutton, R A Burges.   

Abstract

The hemodynamic actions of the new dihydropyridine calcium-channel blocker amlodipine were assessed and compared with those of nitrendipine using anesthetised dogs and were also investigated in conscious dogs with and without beta-adrenergic blockade. After bolus intravenous administration, amlodipine (25 to 1600 micrograms/kg) or nitrendipine (1 to 128 micrograms/kg) was administered to anesthetised dogs at 30-minute intervals, caused dose-related reductions in systemic and coronary vascular resistances with corresponding increases in cardiac output and coronary flow. Nitrendipine, unlike amlodipine, caused marked acute hypotension. The onset of action of amlodipine was markedly slower than that of nitrendipine, and effects were maintained for 30 minutes--recovery from nitrendipine was largely complete at 30 minutes. In conscious dogs, amlodipine (250, 500, 1000 micrograms/kg IV) caused dose-related reductions in systemic vascular resistance that approached maximum within 5 minutes and persisted for over 4 hours. Reflex increases in heart rate, cardiac output, and cardiac contractility were attenuated by prior treatment with propranolol, resulting in earlier and greater falls in blood pressure, but no marked adverse effects on cardiac contraction or conduction. In the absence of propranolol, maximum falls in blood pressure occurred 3 to 4 hours after the dose, possibly as a result of the changed baroceptor sensitivity induced by amlodipine. These results show amlodipine to have the basic hemodynamic profile of other dihydropyridine calcium-channel blockers, but in addition it demonstrates a slower onset and longer duration of action; the reasons behind these pharmacodynamic properties are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577312     DOI: 10.1007/bf01865514

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  MEASUREMENT OF LOCAL BLOOD FLOW WITH HYDROGEN GAS.

Authors:  K AUKLAND; B F BOWER; R W BERLINER
Journal:  Circ Res       Date:  1964-02       Impact factor: 17.367

2.  Pharmacologic properties of minoxidil: a new hypotensive agent.

Authors:  D W DuCharme; W A Freyburger; B E Graham; R G Carlson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

3.  Mechanisms of baroreceptor-induced changes in heart rate.

Authors:  M D Thames; H A Kontos
Journal:  Am J Physiol       Date:  1970-01

4.  Levo-bunolol and propranolol: further evaluation of oral beta-blocking activity in conscious dogs.

Authors:  M A Commarato; E C Giardino; G A Kopia; H R Kaplan
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-04

5.  Efficacy of antihypertensive drugs.

Authors:  G T Dixon; E S Johnson
Journal:  Lancet       Date:  1976-03-06       Impact factor: 79.321

6.  Regional vasodilating and cardiac effects of nicardipine in anaesthetized open chest dog.

Authors:  S Bongrani; R Razzetti; P Schiantarelli
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-02

7.  Effects of calcium channel blockers on isolated carotid baroreceptors and baroreflex.

Authors:  C M Heesch; B M Miller; M D Thames; F M Abboud
Journal:  Am J Physiol       Date:  1983-10

8.  Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: alterations in baroreflex sensitivity.

Authors:  D C Warltier; M G Zyvoloski; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

9.  Contrasting effects of nifedipine, captopril, and propranolol in normotensive and hypertensive subjects.

Authors:  G A MacGregor; C Rotellar; N D Markandu; S J Smith; G A Sagnella
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs.

Authors:  R A Walsh; F R Badke; R A O'Rourke
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

View more
  3 in total

1.  Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.

Authors:  Q Timour; B Bui-Xuan; G Faucon; J F Aupetit
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Cardiac implications of amlodipine-dantrolene combinations.

Authors:  M Freysz; Q Timour; C Bernaud; L Bertrix; G Faucon
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

3.  Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.

Authors:  P Santarelli; F Biscione; A Natale; A Manzoli; G A Lanza
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.